> top > docs > PubMed:30218286 > annotations

PubMed:30218286 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-147 Sentence denotes The Effects of Probiotic Honey Consumption on Metabolic Status in Patients with Diabetic Nephropathy: a Randomized, Double-Blind, Controlled Trial.
T2 148-380 Sentence denotes To the best of our knowledge, this study is the first evaluating the effects of probiotic honey intake on glycemic control, lipid profiles, biomarkers of inflammation, and oxidative stress in patients with diabetic nephropathy (DN).
T3 381-504 Sentence denotes This investigation was conducted to evaluate the effects of probiotic honey intake on metabolic status in patients with DN.
T4 505-602 Sentence denotes This randomized, double-blind, controlled clinical trial was performed among 60 patients with DN.
T5 603-852 Sentence denotes Patients were randomly allocated into two groups to receive either 25 g/day probiotic honey containing a viable and heat-resistant probiotic Bacillus coagulans T11 (IBRC-M10791) (108 CFU/g) or 25 g/day control honey (n = 30 each group) for 12 weeks.
T6 853-1033 Sentence denotes Fasting blood samples were taken at baseline and 12 weeks after supplementation to quantify glycemic status, lipid concentrations, biomarkers of inflammation, and oxidative stress.
T7 1034-1461 Sentence denotes After 12 weeks of intervention, patients who received probiotic honey compared with the control honey had significantly decreased serum insulin levels (- 1.2 ± 1.8 vs. - 0.1 ± 1.3 μIU/mL, P = 0.004) and homeostasis model of assessment-estimated insulin resistance (- 0.5 ± 0.6 vs. 0.003 ± 0.4, P = 0.002) and significantly improved quantitative insulin sensitivity check index (+ 0.005 ± 0.009 vs. - 0.0007 ± 0.005, P = 0.004).
T8 1462-1638 Sentence denotes Additionally, compared with the control honey, probiotic honey intake has resulted in a significant reduction in total-/HDL-cholesterol (- 0.2 ± 0.5 vs. + 0.1 ± 0.1, P = 0.04).
T9 1639-1900 Sentence denotes Probiotic honey intake significantly reduced serum high-sensitivity C-reactive protein (hs-CRP) (- 1.9 ± 2.4 vs. - 0.2 ± 2.7 mg/L, P = 0.01) and plasma malondialdehyde (MDA) levels (- 0.1 ± 0.6 vs. + 0.6 ± 1.0 μmol/L, P = 0.002) compared with the control honey.
T10 1901-2011 Sentence denotes Probiotic honey intake had no significant effects on other metabolic profiles compared with the control honey.
T11 2012-2323 Sentence denotes Overall, findings from the current study demonstrated that probiotic honey consumption for 12 weeks among DN patients had beneficial effects on insulin metabolism, total-/HDL-cholesterol, serum hs-CRP, and plasma MDA levels, but did not affect other metabolic profiles. http://www.irct.ir: IRCT201705035623N115.
T1 0-147 Sentence denotes The Effects of Probiotic Honey Consumption on Metabolic Status in Patients with Diabetic Nephropathy: a Randomized, Double-Blind, Controlled Trial.
T2 148-380 Sentence denotes To the best of our knowledge, this study is the first evaluating the effects of probiotic honey intake on glycemic control, lipid profiles, biomarkers of inflammation, and oxidative stress in patients with diabetic nephropathy (DN).
T3 381-504 Sentence denotes This investigation was conducted to evaluate the effects of probiotic honey intake on metabolic status in patients with DN.
T4 505-602 Sentence denotes This randomized, double-blind, controlled clinical trial was performed among 60 patients with DN.
T5 603-852 Sentence denotes Patients were randomly allocated into two groups to receive either 25 g/day probiotic honey containing a viable and heat-resistant probiotic Bacillus coagulans T11 (IBRC-M10791) (108 CFU/g) or 25 g/day control honey (n = 30 each group) for 12 weeks.
T6 853-1033 Sentence denotes Fasting blood samples were taken at baseline and 12 weeks after supplementation to quantify glycemic status, lipid concentrations, biomarkers of inflammation, and oxidative stress.
T7 1034-1461 Sentence denotes After 12 weeks of intervention, patients who received probiotic honey compared with the control honey had significantly decreased serum insulin levels (- 1.2 ± 1.8 vs. - 0.1 ± 1.3 μIU/mL, P = 0.004) and homeostasis model of assessment-estimated insulin resistance (- 0.5 ± 0.6 vs. 0.003 ± 0.4, P = 0.002) and significantly improved quantitative insulin sensitivity check index (+ 0.005 ± 0.009 vs. - 0.0007 ± 0.005, P = 0.004).
T8 1462-1638 Sentence denotes Additionally, compared with the control honey, probiotic honey intake has resulted in a significant reduction in total-/HDL-cholesterol (- 0.2 ± 0.5 vs. + 0.1 ± 0.1, P = 0.04).
T9 1639-1900 Sentence denotes Probiotic honey intake significantly reduced serum high-sensitivity C-reactive protein (hs-CRP) (- 1.9 ± 2.4 vs. - 0.2 ± 2.7 mg/L, P = 0.01) and plasma malondialdehyde (MDA) levels (- 0.1 ± 0.6 vs. + 0.6 ± 1.0 μmol/L, P = 0.002) compared with the control honey.
T10 1901-2011 Sentence denotes Probiotic honey intake had no significant effects on other metabolic profiles compared with the control honey.
T11 2012-2323 Sentence denotes Overall, findings from the current study demonstrated that probiotic honey consumption for 12 weeks among DN patients had beneficial effects on insulin metabolism, total-/HDL-cholesterol, serum hs-CRP, and plasma MDA levels, but did not affect other metabolic profiles. http://www.irct.ir: IRCT201705035623N115.

yangbin123xm_800_3

Id Subject Object Predicate Lexical cue
T1 80-100 DP denotes Diabetic Nephropathy
T10 679-694 CI denotes probiotic honey
T11 1088-1103 CI denotes probiotic honey
T12 1509-1524 CI denotes probiotic honey
T13 2071-2086 CI denotes probiotic honey
T2 354-374 DP denotes diabetic nephropathy
T3 376-378 DP denotes DN
T4 501-503 DP denotes DN
T5 599-601 DP denotes DN
T6 2118-2120 DP denotes DN
T7 15-30 CI denotes Probiotic Honey
T8 228-243 CI denotes probiotic honey
T9 441-456 CI denotes probiotic honey
T14 805-818 CI denotes control honey
T15 1122-1135 CI denotes control honey
T16 1494-1507 CI denotes control honey
T17 1886-1899 CI denotes control honey
T18 1997-2010 CI denotes control honey
T19 744-766 CI denotes Bacillus coagulans T11
T20 768-779 CI denotes IBRC-M10791

chenxin_473849_800_3

Id Subject Object Predicate Lexical cue
T1 228-243 CI denotes probiotic honey
T2 441-456 CI denotes probiotic honey
T3 679-694 CI denotes probiotic honey
T4 1088-1103 CI denotes probiotic honey
T5 1509-1524 CI denotes probiotic honey
T6 2071-2086 CI denotes probiotic honey
T7 15-30 CI denotes Probiotic Honey
T8 744-766 CI denotes Bacillus coagulans T11
T9 768-779 CI denotes IBRC-M10791
T10 805-818 CI denotes control honey
T11 1122-1135 CI denotes control honey
T12 1494-1507 CI denotes control honey
T13 1886-1899 CI denotes control honey
T14 1997-2010 CI denotes control honey
T15 354-374 DP denotes diabetic nephropathy
T16 376-378 DP denotes DN
T17 501-503 DP denotes DN
T18 599-601 DP denotes DN
T19 2118-2120 DP denotes DN
T20 80-100 DP denotes Diabetic Nephropathy